<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02942563</url>
  </required_header>
  <id_info>
    <org_study_id>2016CRC R-001</org_study_id>
    <nct_id>NCT02942563</nct_id>
  </id_info>
  <brief_title>Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer</brief_title>
  <official_title>A Phase II Study of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RenJi Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>RenJi Hospital</source>
  <brief_summary>
    <textblock>
      The concurrent neoadjuvant chemoradiation therapy is standard care for local advanced rectal&#xD;
      cancer (LARC), however, this regimen may induce sorts of adverse events, and part of them&#xD;
      even more severer. A number of pilot studies had shown high rate of complete resection after&#xD;
      neoadjuvant chemotherapy alone, but the results did not increase the ratio of pathological&#xD;
      complete response (pCR), which was associated with overall survival (OS). Here, the&#xD;
      investigators adopt the three active cytotoxic agents (Fluorouracil, Oxaliplatin, Irinotecan,&#xD;
      FOLFOXIRI) as the neoadjuvant chemotherapy regimen to replace the concurrent chemoradiation&#xD;
      and to improve the ratio of pCR further.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, phase II trial to assess the efficacy/safety of triplet regimen&#xD;
      (FOLFOXIRI) for patients with LARC. After 4 cycles of FOLFOXIRI and 2 weeks later, the&#xD;
      patients will be evaluated by senior radiologist, oncologist and surgeon through pelvic MRI,&#xD;
      CT and Positron Emission Computed Tomography (PET-CT). The patients will go to surgery (TME)&#xD;
      if the tumor response is good enough to have complete resection under the decision of&#xD;
      MDT,otherwise, the patients will receive pelvic radiotherapy(45Grey/25Fraction and&#xD;
      5.4Grey/3Fraction boost to the tumor bed) combined with capecitabine(625mg/M^2, bid po, d1-5,&#xD;
      qw), and additional four cycles of modified FOLFOX6 (mFOLFOX6) or Oxaliplatin 135mg/m²plus&#xD;
      Capecitabine 1.0/m² bid po(XELOX) of each 3 weeks cycle for 2 cycles chemotherapy before TME.&#xD;
      All patients will receive 6-8 cycles of mFOLFOX6 or 4-5 cycles XELOX as adjuvant chemotherapy&#xD;
      after TME.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2016</start_date>
  <completion_date type="Anticipated">September 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pelvic complete resection rate</measure>
    <time_frame>Up to 10 weeks</time_frame>
    <description>Pathologic confirmation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The rate of local control</measure>
    <time_frame>3 years</time_frame>
    <description>Imaging diagnosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease free survival (DFS)</measure>
    <time_frame>3 years</time_frame>
    <description>Imaging diagnosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>3 years</time_frame>
    <description>Record document</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rate of receive chemoradiation</measure>
    <time_frame>Up to 10 weeks</time_frame>
    <description>Record document</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rate of clinical complete response after 4 cycles of FOLFOXIRI</measure>
    <time_frame>Up to 10 weeks</time_frame>
    <description>Imaging diagnosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rate of pathological complete response after 4 cycles of FOLFOXIRI</measure>
    <time_frame>Up to 10 weeks</time_frame>
    <description>Pathologic confirmation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of &gt;=3 grade adverse events</measure>
    <time_frame>2 years</time_frame>
    <description>Common Terminology Criteria for Adverse Events v3.0 (CTCAE)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Rectal Cancer</condition>
  <arm_group>
    <arm_group_label>FOLFOXIRI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>irinotecan* 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 2800 mg/m² cont. inf. 46h all on day 1 of each 2 weeks cycle</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FOLFOXIRI</intervention_name>
    <description>Irinotecan* 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 2800 mg/m² cont. inf. 46h all on day 1 of each 2 weeks cycle for 4-6 cycles,&#xD;
Chemoradiation for patients who are not suitable to surgery:&#xD;
Pelvic radiotherapy(45Grey/25Fraction and 5.4Grey/3Fraction boost to the tumor bed) combined with capecitabine(625mg/m², bid po, d1-5, qw), and additional four cycles of modified FOLFOX6 (mFOLFOX6) or Oxaliplatin 135mg/m²plus Capecitabine 1.0/m² bid po(XELOX) of each 3 weeks cycle for 2 cycles chemotherapy before TME.&#xD;
All patients will receive 6-8 cycles of mFOLFOX6 or 4-5 cycles XELOX as adjuvant chemotherapy after TME.</description>
    <arm_group_label>FOLFOXIRI</arm_group_label>
    <other_name>Irinotecan</other_name>
    <other_name>Oxaliplatin</other_name>
    <other_name>5-FU</other_name>
    <other_name>Capecitabine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18 to 75 years at diagnosis&#xD;
&#xD;
          -  Diagnosis of rectal adenocarcinoma&#xD;
&#xD;
          -  ECOG status: 0～1&#xD;
&#xD;
          -  Clinical stage II (T3-4, N0) or stage III (T1-4, N1-2)&#xD;
&#xD;
          -  Adequate bone marrow, hepatic and renal function as assessed by the following&#xD;
             laboratory requirements conducted within 7 days of starting study treatment:&#xD;
&#xD;
          -  Leukocytes ≥ 4.0 x109/ L,&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) ≥ 2.0 x109/ L&#xD;
&#xD;
          -  Platelet count ≥ 100 x109/ L,&#xD;
&#xD;
          -  Hemoglobin (Hb) ≥ 9g/ dL.&#xD;
&#xD;
          -  Total bilirubin ≤1.5 x the upper limit of normal (ULN).&#xD;
&#xD;
          -  Alanine aminotransferase (ALT) ≤ 3 x ULN&#xD;
&#xD;
          -  Aspartate aminotransferase (AST) ≤ 3 x ULN.&#xD;
&#xD;
          -  Serum creatinine ≤ 1.5 x the ULN.&#xD;
&#xD;
          -  Signed informed consent;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient had received pelvic radiotherapy&#xD;
&#xD;
          -  Patient had received systemic chemotherapy&#xD;
&#xD;
          -  Pregnant and Nursing women&#xD;
&#xD;
          -  Had metastatic disease&#xD;
&#xD;
          -  Uncontrolled co-morbid illnesses or other concurrent disease&#xD;
&#xD;
          -  Patient had second malignant disease within 5 years&#xD;
&#xD;
          -  Patients refused to signed informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ming Ye, Master</last_name>
    <role>Principal Investigator</role>
    <affiliation>Locations: China, Shanghai Shanghai Jiaotong University School of Medicine, Renji Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ming Ye, Master</last_name>
    <phone>+862168383459</phone>
    <email>renjiyeming@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Qi Lu, Master</last_name>
    <phone>+862158752345</phone>
    <phone_ext>33364</phone_ext>
    <email>luqi@renji.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ethics Committee of Renji Hospital, School of Medicine,Shanghai Jiaotong University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200127</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ming Ye, Master</last_name>
      <phone>+862168383459</phone>
      <email>renjiyeming@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Qi Lu, Master</last_name>
      <phone>+862158752345</phone>
      <phone_ext>33364</phone_ext>
      <email>luqi@renji.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <study_first_submitted>October 21, 2016</study_first_submitted>
  <study_first_submitted_qc>October 21, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 24, 2016</study_first_posted>
  <last_update_submitted>January 1, 2018</last_update_submitted>
  <last_update_submitted_qc>January 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Local Advanced Rectal Cancer</keyword>
  <keyword>Total Neoadjuvant Therapy</keyword>
  <keyword>FOLFOXIRI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

